News | Latest Breaking News Stories & Headlines

Roche's diagnostics revenue, including from Covid tests, rose by 28% in the fourth quarter of 2020

Roche's Q4 sales helped by Covid-19 test business

Swiss drugmaker Roche got a fourth-quarter lift from its Covid-19 test business, where higher sales offset a decline at its drugs unit whose revenue was dragged down by the pandemic and patent-expired cancer drugs that lost ground to rivals.

Business • 04 Feb 21

Roche confirms 2020 outlook as Covid diagnostics surge

The frantic global effort to test people for Covid-19 pushed Roche's diagnostics division to record revenue, helping the Swiss drugmaker offset declining drug sales and keeping it on track to meet full-year 2020 targets.

Business • 15 Oct 20

Anne Cusack and Seamus Reilly, Founders of Critical Healthcare

Offaly-based PPE provider reports rapid growth

Critical Healthcare, a provider of frontline medical products including PPE, has reported rapid growth as a result of the Covid-19 pandemic.

Business • 02 Oct 20

Dr Manus Rogan, Chairman & co-founding investor of Inflazome, Dr Matt Cooper, co-founder & CEO, Professor Luke O'Neill, co-founder & Chief Scientific Officer and Dr Jeremy Skillington, Vice President, Business Development

Biotech firm Inflazome bought by Roche for €380m

Irish biotech company Inflazome has been acquired by Swiss multinational healthcare company Roche for €380m.

Business • 21 Sep 20

Roche said it is 'going to the limits of production capacity' to deliver as many of the faster tests as possible

New Roche coronavirus test wins emergency US approval

The US Food and Drug Administration (FDA) has issued emergency authorisation for a faster coronavirus test made by Swiss diagnostics maker Roche.

Business • 02 Sep 21

Germany's Federal Institute for Drugs and Medical Devices has ordered the country's main drug industry associations to gather information on the effect of a no-deal Brexit

Germany advises drug makers to examine supply chain

German drug makers have been asked by the government to examine their supply chains for any vulnerability that could cause shortages of essential drugs in the event that Britain leaves the European Union without a Brexit deal.

Business • 29 Aug 18

Roche will pay $27 per share for Ignyta, representing a premium of about 74% to the stock's closing price yesterday

Roche to buy US cancer drugmaker Ignyta for $1.7bn

Swiss drugmaker Roche will buy US cancer drugmaker Ignyta for $1.7 billion to broaden its oncology portfolio globally, the companies said today.

Business • 22 Dec 17

Roche announced in May that talks with another international pharmaceutical plant to buy the Clarecastle had failed

Minister criticised over Roche job losses

Minister for Jobs, Enterprise and Innovation Mary Mitchell O'Connor has been criticised by a party colleague for not doing enough to save the 240 jobs at the Roche pharmaceutical plant in Clarecastle in Co Clare.

News • 05 Jul 16

Roche Holding AG had been based in Clarecastle since 1974

Efforts to save 240 jobs in Clare unsuccessful

The Roche pharmaceutical plant in Clarecastle, Co Clare has confirmed that negotiations to buy its facility in the town and save some of the 240 jobs there have been unsuccessful, and the plant will close.

Business • 17 May 16

New deal to boost the Swiss drugmaker's personalised cancer treatments

Roche to buy majority stake in Foundation

Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, it said today.

Business • 12 Jan 15

Roche has in recent years boasted one of the most productive research pipelines in the industry

Double blow for Roche as studies fail

Roche is to discontinue a late-stage study of an experimental Alzheimer's drug after it failed to prove effective.

Business • 19 Dec 14

Roche's CEO said the acquisition would allow it to broaden its portfolio, particularly in the area of respiratory drugs

Roche to acquire InterMune in $8.3bn deal

Roche Holding has agreed to buy US biotech company InterMune for $8.3bn in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

Business • 25 Aug 14